SCF ENCYCLOPEDIA ENTRY

HEPATITIS B & HEPATITIS C IN PREGNANCY

SCF-RDOS Maternal–Fetal Viral Transmission, Hepatic Immunobiology & Perinatal Infectious Disease Registry

Disease Classification:

Maternal Viral Infection / Perinatal Infectious Disease / Vertical Transmission Syndrome / Chronic Hepatotropic Viral Disease / Maternal–Fetal Immune Interface Disorder

Master Registry Code:

SCF-HBVHCV-PREG-0001

I. DEFINITION

Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections in pregnancy are maternal viral diseases with the potential to affect maternal liver health and transmit infection to the fetus or newborn.

The primary concern during pregnancy is:

• Vertical transmission
• Maternal hepatic disease progression
• Neonatal infection risk
• Long-term chronic liver disease in offspring

HBV and HCV differ substantially in their transmission dynamics, prevention strategies, and neonatal management.

Within the Synergistic Compatibility Framework (SCF), hepatitis B and C in pregnancy are modeled as:

• Maternal–fetal viral interface disorders
• Vertical transmission synchronization failure syndromes
• Hepatic immune adaptation diseases
• Developmental infectious programming architectures

II. CORE SCF ETIOPATHOGENIC PRINCIPLE

Central SCF Thesis

Hepatitis B and C in pregnancy arise when chronic maternal viral reservoirs interact with placental, immune, and fetal developmental systems. Disease risk emerges from failure of maternal–fetal viral containment mechanisms, allowing viral persistence, placental exposure, neonatal infection, and long-term host adaptation.

This propagates through:

1. Maternal viral infection
2. Viral persistence
3. Maternal–fetal interface exposure
4. Vertical transmission risk
5. Neonatal infection
6. Chronic viral adaptation
7. Long-term hepatic consequences

III. MAJOR REGISTRY

A. CHRONIC HEPATITIS B IN PREGNANCY

Most Common Global Cause

Characteristics:

• Chronic HBV carriage
• High maternal viral load
• Significant vertical transmission risk

Without intervention:

• Transmission may exceed 90% in high-risk cases.

B. ACUTE HEPATITIS B IN PREGNANCY

Less common.

Features:

• New infection during pregnancy
• Maternal hepatitis
• Increased transmission risk

C. CHRONIC HEPATITIS C IN PREGNANCY

Most common HCV presentation.

Features:

• Persistent maternal viremia
• Lower transmission rates than HBV
• No neonatal vaccine currently available

D. ACUTE HEPATITIS C IN PREGNANCY

Rare.

May present with:

• Elevated liver enzymes
• Viremia
• Acute hepatic inflammation

IV. ETIOLOGIC DOMAINS

A. MATERNAL VIRAL RESERVOIR

Persistent infection occurs within:

HBV

• Hepatocytes
• cccDNA reservoirs

HCV

• Hepatocytes
• Viral replication complexes

B. PLACENTAL INTERFACE EXPOSURE

Potential transmission pathways include:

• Placental microtransfusion
• Intrapartum exposure
• Blood contact during delivery

C. MATERNAL IMMUNE ADAPTATION

Pregnancy alters:

• Antiviral immunity
• Cytokine signaling
• Immune tolerance pathways

D. VIRAL LOAD

One of the strongest predictors of transmission.

Particularly important for:

• HBV

E. CO-INFECTIONS

Risk increases with:

• HIV coinfection
• Immunosuppression
• Liver disease progression

Associated with:

• Human Immunodeficiency Virus Infection

V. SCF MULTI-OMIC PATHOGENESIS

A. VIRAL PERSISTENCE LAYER

Viruses establish:

• Long-term reservoirs
• Immune evasion strategies
• Chronic infection states

B. HEPATIC INJURY LAYER

Results from:

• Immune-mediated hepatocyte damage
• Chronic inflammation
• Fibrosis progression

C. PLACENTAL INTERFACE LAYER

Maternal blood and placental tissues form:

• Viral containment barriers
• Transmission control systems

D. VERTICAL TRANSMISSION LAYER

Occurs through:

• In utero exposure
• Peripartum exposure
• Delivery-associated blood contact

E. NEONATAL ADAPTATION LAYER

Neonatal immune systems possess:

• Reduced viral clearance capacity
• Increased chronic infection susceptibility

F. CHRONIC DISEASE PROGRAMMING LAYER

Persistent infection may eventually lead to:

• Fibrosis
• Cirrhosis
• Hepatocellular carcinoma

Associated with:

• Cirrhosis

VI. HBV VS HCV TRANSMISSION ARCHITECTURE

VII. SCF FAULT-TIER ARCHITECTURE

SCF fault progression models hepatitis infection in pregnancy as escalation from maternal viral persistence into neonatal chronic infectious programming.

VIII. MAJOR MATERNAL CLINICAL MANIFESTATIONS

A. ASYMPTOMATIC INFECTION

Most common presentation.

Particularly:

• Chronic HBV
• Chronic HCV

B. HEPATIC FINDINGS

Includes

• Elevated AST
• Elevated ALT
• Hepatomegaly
• Fatigue

C. ADVANCED LIVER DISEASE

May include:

• Portal hypertension
• Cirrhosis
• Hepatic insufficiency

D. PREGNANCY COMPLICATIONS

Associations reported with:

• Gestational diabetes
• Cholestasis
• Preterm birth

Associated with:

• Gestational Diabetes Mellitus

IX. FETAL & NEONATAL CONSEQUENCES

HBV

Without prophylaxis:

• High neonatal infection rates
• Chronic hepatitis risk

HCV

Possible outcomes:

• Vertical transmission
• Chronic pediatric infection

Long-Term Consequences

Potential development of:

• Chronic hepatitis
• Fibrosis
• Cirrhosis
• Hepatocellular carcinoma

Associated with:

• Hepatocellular Carcinoma

X. SCF RHENOVA INTERPRETATION

Within the SCF–RHENOVA model, hepatitis B and C in pregnancy represent:

• Maternal viral bioenergetic variance
• Hepatic adaptation burden
• Maternal–fetal infectious interface instability

Key RHENOVA Signatures

• Chronic inflammation
• Oxidative stress
• Hepatic remodeling
• Immune adaptation pressure
• Viral persistence

XI. SCF DBI INTERPRETATION

Under the SCF Decentralized Biological Intelligence (DBI) framework, HBV and HCV disrupt:

• Maternal antiviral defense systems
• Hepatic regulatory networks
• Placental communication pathways
• Neonatal immune adaptation algorithms
• Maternal–fetal infectious containment architecture

This transforms chronic viral persistence into developmental infectious risk.

XII. QUANTUM & HOST–VIRUS HOMEOSTASIS INTERPRETATION

Within SCF Quantum Medicine:

• Pregnancy requires coordinated tolerance between maternal, placental, and fetal systems.
• Chronic viral infection introduces competing biologic information streams.
• Disease emerges when viral persistence exceeds containment capacity at the maternal–fetal interface.

XIII. DIAGNOSTIC ARCHITECTURE

Universal Screening

Hepatitis B

Recommended during pregnancy.

Tests:

• HBsAg
• HBV DNA
• Liver function tests

Hepatitis C

Increasingly recommended in universal prenatal screening.

Tests:

• Anti-HCV antibody
• HCV RNA

Maternal Evaluation

Includes:

• Viral load assessment
• Fibrosis evaluation
• Liver function testing

XIV. SCF PCR MODEL (PREVENTATIVE–CURATIVE–RESTORATIVE)

A. PREVENTATIVE

HBV Prevention

Maternal antiviral therapy may be used for:

• High viral load

Common agent:

Tenofovir Disoproxil Fumarate

Neonatal HBV Prevention

Immediately after birth:

• Hepatitis B vaccine
• Hepatitis B immune globulin (HBIG)

These measures dramatically reduce transmission.

HCV Prevention

Currently:

• No vaccine
• No approved neonatal immunoprophylaxis

Primary focus:

• Identification and monitoring

B. CURATIVE

Maternal Management

HBV:

• Viral load suppression
• Liver monitoring

HCV:

• Postpartum antiviral treatment planning

Neonatal Management

Includes:

• Serologic follow-up
• Infection surveillance
• Long-term liver monitoring if infected

C. RESTORATIVE

Long-Term Recovery

• Maternal liver surveillance
• Pediatric infectious disease follow-up
• Fibrosis prevention
• Chronic disease monitoring

XV. ORIGIN-OF-DISEASE & CYTOGENESIS PROGRESSION TIMELINE

Cytogenesis Loci

Primary loci:

• Hepatocytes
• Placenta
• Maternal circulation
• Neonatal liver

Secondary loci:

• Immune system
• Lymphoid tissues
• Fibrotic pathways
• Hepatic stem-cell niches

XVI. REGULATORY & CLINICAL MANAGEMENT FRAMEWORK

Relevant clinical domains:

• Maternal-Fetal Medicine
• Hepatology
• Infectious Disease
• Neonatology
• Pediatric Hepatology

Therapeutic development requires:

• Maternal–fetal safety monitoring
• Viral load surveillance
• Long-term hepatic outcome assessment
• Pediatric infectious disease follow-up

XVII. SCF API DISCOVERY & THERAPEUTIC PRIORITIES

Potential Therapeutic Domains

• Maternal–fetal antiviral interface therapies
• Viral reservoir suppressors
• Placental barrier enhancement systems
• Neonatal immune-training platforms
• Functional HBV cure technologies
• HCV eradication therapeutics

Safety Requirements

All interventions require:

• Maternal–fetal safety evaluation
• Hepatic function monitoring
• Viral surveillance
• Long-term offspring outcome assessment

XVIII. SCF SUMMARY

Hepatitis B & Hepatitis C in Pregnancy = Maternal–Fetal Viral Containment and Hepatic Homeostasis Synchronization Failure Syndromes

Within SCF:

• HBV and HCV represent chronic maternal viral reservoirs capable of affecting fetal and neonatal health.
• Vertical transmission is the principal developmental concern.
• HBV has effective prevention through maternal screening, antiviral therapy when indicated, vaccination, and neonatal HBIG administration.
• HCV currently lacks neonatal immunoprophylaxis and remains dependent upon screening and postnatal monitoring.
• Future therapeutic strategies focus on viral reservoir elimination, maternal–fetal transmission prevention, placental protection, and optimization of neonatal immune adaptation.

MASTER REGISTRY INDEX

SCF-HBVHCV-PREG-0001 — Hepatitis B & C in Pregnancy

SCF-HBVHCV-VIRAL-0002 — Maternal Viral Reservoir Layer

SCF-HBVHCV-PLACENTA-0003 — Maternal–Placental Interface Layer

SCF-HBVHCV-TRANS-0004 — Vertical Transmission Layer

SCF-HBVHCV-RHENOVA-0005 — Viral Bioenergetic Variance Layer

SCF-HBVHCV-DBI-0006 — Maternal–Fetal Infectious Informational Dysregulation Layer